Details for Patent: 9,481,663
✉ Email this page to a colleague
Which drugs does patent 9,481,663 protect, and when does it expire?
Patent 9,481,663 protects ERLEADA and is included in one NDA.
This patent has ninety-seven patent family members in forty-one countries.
Summary for Patent: 9,481,663
| Title: | Crystalline forms of an androgen receptor modulator |
| Abstract: | Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspir- o[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity. |
| Inventor(s): | Dilhas; Anna (Basel, CH), Herbert; Mark R (San Diego, CA), Ouerfelli; Ouathek (Fort Lee, NJ), Smith; Nicholas D (San Diego, CA) |
| Assignee: | Aragon Pharmaceuticals, Inc. (San Diego, CA) Sloan-Kettering Institute For Cancer Research (New York, NY) |
| Application Number: | 14/406,520 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,481,663 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Dosage form; |
Drugs Protected by US Patent 9,481,663
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-001 | Feb 14, 2018 | RX | Yes | No | 9,481,663 | ⤷ Subscribe | Y | Y | TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC) | ⤷ Subscribe | ||
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-001 | Feb 14, 2018 | RX | Yes | No | 9,481,663 | ⤷ Subscribe | Y | Y | TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC) | ⤷ Subscribe | ||
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-002 | Feb 17, 2023 | RX | Yes | Yes | 9,481,663 | ⤷ Subscribe | Y | Y | TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC) | ⤷ Subscribe | ||
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-002 | Feb 17, 2023 | RX | Yes | Yes | 9,481,663 | ⤷ Subscribe | Y | Y | TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC) | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,481,663
| PCT Information | |||
| PCT Filed | June 04, 2013 | PCT Application Number: | PCT/US2013/044116 |
| PCT Publication Date: | December 12, 2013 | PCT Publication Number: | WO2013/184681 |
International Family Members for US Patent 9,481,663
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3533792 | ⤷ Subscribe | 301144 | Netherlands | ⤷ Subscribe |
| European Patent Office | 3533792 | ⤷ Subscribe | PA2021525 | Lithuania | ⤷ Subscribe |
| European Patent Office | 3533792 | ⤷ Subscribe | CA 2021 00041 | Denmark | ⤷ Subscribe |
| European Patent Office | 3533792 | ⤷ Subscribe | 122021000067 | Germany | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
